Advertisement
Microbot Medical Announces Positive Results For GLP Pivotal Pre-Clinical Study; Stock Up 15%
(RTTNews) - Microbot Medical Inc. (MBOT) announced Thursday the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations.
The target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endovascular Robotic Surgical System.
The company said it continues to transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase. The company expects to submit its IDE application to the FDA soon and commence the pivotal human clinical trial.
Canadian Dollar Falls Against Most Majors
Canadian Market Modestly Higher; Technology Stocks Among Notable Gainers
Swiss Market Ends Marginally Up
Major European Markets Close On Mixed Note
Positive Start Seen For Canadian Stocks
UK Market Roughly Flat; Mining Stocks Move Higher
CAC 40 Climbs Higher For 3rd Straight Day
